Category: Finance

Analysis, Finance, Internet, Mobile

Facebook Stock impacted by NASDAQ:FB Business News : Outage, Android App and Slingshot

(NASDAQ:FB) This is TechNews.org selection of financial news on Facebook and the Facebook stock NASDAQ:FB, with the business impact of the new Facebook Android App, the Facebook outage and the promising Facebook’s Slingshot mobile application. Facebook is now back at 100% after a 30-minute outage. Facebook (NASDAQ:FB) is fully operational after a 30-minute outage which affected the social network’s web and mobile site as well … Continue reading Facebook Stock impacted by NASDAQ:FB Business News : Outage, Android App and Slingshot

Harvey Dyer
GE NYSE GE General Electric Stock Financial News
Analysis, Finance, Software

GE Alstom Deal : Impact on General Electric (NYSE:GE) Stock and Financial News + Video

France’s socialist government has claimed a resounding victory for state intervention after forcing General Electric (NYSE:GE) to significantly revise its $16.9bn takeover deal for Alstom’s energy businesses, which both companies approved at the weekend. The government announced on Sunday night it had agreed terms with the French conglomerate Bouygues for its purchase of a 20 per cent state stake in Alstom, worth about €1.7bn at … Continue reading GE Alstom Deal : Impact on General Electric (NYSE:GE) Stock and Financial News + Video

John Meady
Finance

Biotech Bearish Stocks: Zalicus Inc (NASDAQ:ZLCS), Stemline Therapeutics Inc (NASDAQ:STML), Agenus Inc (NASDAQ:AGEN), Arrowhead Research Corp (NASDAQ:ARWR), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Zalicus Inc (NASDAQ:ZLCS) on June 18 announced that it has licensed its Sodium Channel Modulator program, including intellectual property and related pipeline assets, to AnaBios Corporation in exchange for clinical milestone payments and royalties on potential future sales. Under the terms of the agreement Zalicus will be eligible to receive up to $17.2 million in clinical and regulatory milestone payments and up to 12% of … Continue reading Biotech Bearish Stocks: Zalicus Inc (NASDAQ:ZLCS), Stemline Therapeutics Inc (NASDAQ:STML), Agenus Inc (NASDAQ:AGEN), Arrowhead Research Corp (NASDAQ:ARWR), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Kevin Long
Finance

Biotech Insider Buying: OvaScience Inc (NASDAQ:OVAS), BioTime (NYSEMKT:BTX), Insys Therapeutics (NASDAQ:INSY), Novavax (NASDAQ:NVAX), ImmuCell Corporation (NASDAQ:ICCC)

Ovascience Inc (NASDAQ:OVAS) major shareholder Fund L.P. Longwood bought 100,000 shares of the company’s stock on the open market in a transaction dated Friday, March 7th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $1,000,000.00. OvaScience Inc (NASDAQ:OVAS) stock performance was -2.98% in last session and finished the day at $8.47. Traded volume was 69,618.00million shares … Continue reading Biotech Insider Buying: OvaScience Inc (NASDAQ:OVAS), BioTime (NYSEMKT:BTX), Insys Therapeutics (NASDAQ:INSY), Novavax (NASDAQ:NVAX), ImmuCell Corporation (NASDAQ:ICCC)

Jason Knox
Finance

Consumer Goods Watch List: British American Tobacco PLC (ADR) (NYSEMKT:BTI), Energizer Holdings, Inc. (NYSE:ENR), Vince Holding Corp (NYSE:VNCE), Anheuser Busch Inbev SA (ADR) (NYSE:BUD), Unilever N.V. (ADR) (NYSE:UN)

The Danish tobacco girant, House of Prince, which is owned by British American Tobacco PLC (ADR) (NYSEMKT:BTI), reported pre-tax profits of 1.2 billion kroner in 2013, representing an increase of 32 percent on its 2012 results. British American Tobacco PLC (ADR) (NYSEMKT:BTI) stock performance was 1.04% in last session and finished the day at $122.60. Traded volume was 210,665.00million shares in the last session and … Continue reading Consumer Goods Watch List: British American Tobacco PLC (ADR) (NYSEMKT:BTI), Energizer Holdings, Inc. (NYSE:ENR), Vince Holding Corp (NYSE:VNCE), Anheuser Busch Inbev SA (ADR) (NYSE:BUD), Unilever N.V. (ADR) (NYSE:UN)

Jayne Crisman
Finance

Biotech Unusual Volume: Aldeyra Therapeutics (NASDAQ:ALDX), Alcobra (NASDAQ:ADHD), Receptos (NASDAQ:RCPT), Celsus Therapeutics (NASDAQ:CLTX)

Aldeyra Therapeutics Inc (NASDAQ:ALDX) rallied to a new all-time high Thursday after Aegis Capital began coverage of the biotech company working to develop treatments for rare skin and eye diseases with a Buy rating. Aldeyra Therapeutics Inc (NASDAQ:ALDX) stock performance was 12.26% in last session and finished the day at $7.51. Traded volume was 134,905.00million shares in the last session and the average volume of … Continue reading Biotech Unusual Volume: Aldeyra Therapeutics (NASDAQ:ALDX), Alcobra (NASDAQ:ADHD), Receptos (NASDAQ:RCPT), Celsus Therapeutics (NASDAQ:CLTX)

John Meady